FAQ
Frequently asked questions
Clear answers about wallet credit, usage, subscriptions, and how Tycoon charges for work.
How did Medvi reach $401M in revenue in 12 months with just two people?
Gallagher did not build a product from scratch. He combined three already-existing systems — telehealth infrastructure (CareValidate, OpenLoop), compounding pharmacies, and Meta/TikTok ads — and wrapped them in a single funnel optimized for GLP-1 demand. AI (ChatGPT, Claude, Grok, all publicly credited) handled the operational load that would normally require dozens of employees: code, copy, website, customer service scripts. Comparison point from the same period: Hims & Hers did ~$2.4B in revenue with 2,442 employees at a 5.5% net margin, while Medvi did $401M with 2 people at a 16.2% net margin.
Is Medvi really a 'one-person company' if it has 2 employees and outsourced partners?
Strictly speaking, no — but it is the clearest proof yet that a 2-person team with AI and outsourced licensed partners can run a multi-hundred-million-dollar operation. The clinical side (physicians, pharmacists, fulfillment) is handled by CareValidate and OpenLoop, which is the only legal path to operate in telehealth. The important shift is not the exact headcount, but the ratio: roughly 1 employee per 125,000 customers, versus one employee per ~100 customers at a traditional telehealth brand. That is the compression AI enables.
What regulatory risk does Medvi face after the FDA warning letter?
Significant. In December 2025 the FDA sent Medvi a formal warning letter citing misleading claims like 'Same active ingredient as Wegovy and Ozempic' and labeling that implied Medvi itself was the compounder when it is not. Separately, a chunk of the compounded-GLP-1 category was built on drug-shortage exemptions that are narrowing as supply normalizes. Coverage in Techdirt and HealthDataConsortium has questioned whether the NYT piece underweighted these risks. The lesson for solo founders in regulated verticals: go-to-market speed must be paired with a maturing compliance posture, or the business you built in 12 months can be legislated away in 6.
Could a non-marketer replicate Medvi's playbook today?
Partially. The most transferable parts are the operating model (AI as general operator, outsourced licensed roles, one person at the top making capital and category decisions) and the funnel pattern (narrow landing page, fast intake, subscription billing). The non-transferable part is Gallagher's decade of affiliate marketing and direct-response experience, which let him buy media profitably on day one. A non-marketer can still replicate the operating model in a category that is less CAC-driven — SaaS, info products, B2B services, or community-driven commerce.
What does Medvi tell us about the 'one-person billion-dollar company' prediction?
Medvi is the most credible real-world data point yet. Sam Altman predicted in late 2024 that we would see a one-person billion-dollar company, and Dario Amodei put his confidence for 2026 at 70-80%. Medvi does not yet cross the billion-dollar revenue line, but its 2026 projection ($1.8B) would. More importantly, it demonstrates that the bottleneck is no longer the amount of work a single founder can ship — it is the judgment calls about category, compliance, and capital allocation. That reshapes what kind of person 'founder' means in 2026.